Related Experiment Video
Updated: Jan 7, 2026
Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
Published on: February 16, 2015
Advances and challenges in CAR-T therapy for glioblastoma
Hyeri Ryou1, Sang-Eun Jung2, Hyungseok Seo2
1Laboratory of Cell & Gene Therapy, College of Pharmacy, Seoul National University, Seoul 08826, South Korea.
Abstract:
Glioblastoma (GBM) remains one of the most lethal primary brain tumors, with current standard therapies conferring only limited survival benefit. Although immunotherapeutic approaches have expanded treatment options, they have yet to demonstrate consistent and durable efficacy. Chimeric antigen receptor (CAR)-T cell therapy has emerged as a promising platform with the potential to overcome critical limitations of existing strategies. This review highlights the unique advantages of CAR-T therapy in complementing both standard and immune-based treatments. It further summarizes clinical outcomes reported to date, encompassing completed and ongoing trials, and underscores recurring barriers such as antigen heterogeneity, limited persistence, and the profoundly immunosuppressive tumor microenvironment. In view of these challenges, we discuss emerging strategies to advance CAR-T therapy in GBM, including approaches to broaden antigen recognition, enhance effector function, improve safety, and explore alternative cellular platforms. With continued innovation and rigorous clinical evaluation, CAR-T therapy holds considerable promise for delivering meaningful and durable benefit to patients with GBM.
Insights
Chimeric antigen receptor (CAR)-T cell therapy shows promise for glioblastoma (GBM), a lethal brain tumor. Despite challenges like tumor microenvironment and antigen issues, new strategies aim to improve CAR-T efficacy for better patient outcomes.
Area of Science:
- Neuro-oncology
- Immunotherapy
- Cellular Therapy
Background:
- Glioblastoma (GBM) is a highly lethal primary brain tumor with limited treatment efficacy.
- Current immunotherapies offer potential but lack consistent, durable responses.
- Chimeric antigen receptor (CAR)-T cell therapy presents a novel approach to overcome GBM treatment limitations.
Purpose of the Study:
- To review the advantages of CAR-T cell therapy in GBM treatment.
- To summarize clinical outcomes and identify challenges of CAR-T therapy in GBM.
- To discuss emerging strategies for advancing CAR-T therapy in GBM.
Main Methods:
- Review of existing literature on CAR-T cell therapy for glioblastoma.
- Analysis of clinical trial outcomes and reported efficacy.
- Discussion of challenges including antigen heterogeneity, T-cell persistence, and the tumor microenvironment.
- Exploration of novel strategies to enhance CAR-T therapy effectiveness.
Main Results:
- CAR-T therapy offers unique advantages complementing standard and immune-based treatments for GBM.
- Clinical outcomes show promise but are hampered by antigen heterogeneity, limited persistence, and immunosuppressive tumor microenvironment.
- Emerging strategies focus on broadening antigen recognition, enhancing effector function, improving safety, and exploring alternative platforms.
Conclusions:
- CAR-T cell therapy holds significant promise for treating glioblastoma.
- Addressing challenges in antigen targeting, persistence, and the tumor microenvironment is crucial.
- Continued innovation and clinical evaluation are essential to realize the full potential of CAR-T therapy for GBM patients.
More Related Videos
Related Concept Videos
01:27Tumor Immunotherapy
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...